POD65

[TVR5 @TVR5AVCT]

The deadline for this application was 6+ weeks after #AVCT first dosed AVA6103.

Both Q2W & Q3W dose escalations will have occurred in this period.

The clearest signal yet that AVA6103 is extending the release of Exatecan in human, just as it was designed.

Pharma on notice.

[TVR5 @TVR5AVCT]

TVR5 will stamp its feet if it believes the company is veering off track for a second.

Our feet are raised.

#AVCT

[TVR5 @TVR5AVCT]

We look forward to Richard Hughes being formally appointed Chair of #AVCT on Monday.

#Hughes4Chair ✅

[Cumulus @Cumulus51896691]

Without a convenient box to put it in, the industry has by and large ignored Avacta's technology and promise for many years. Fitting then that an industry outsider takes the chair at a time when a breakthrough seems closer than ever. The stars line up for this at last. #avct

[TVR5 @TVR5AVCT]

Congratulations to Richard Hughes on his appointment as Chair of #AVCT.

@TVR5AVCT looks forward to a transformative H2 under his chairmanship.

We wish Shaun Chilton all the best for the future.

[Richard Hughes @hughesy0707]

In my personal view 2026 will be a defining point for #AVCT and ultimately for long term cancer patients.

Thanks to all shareholders and stakeholders for their support.

[Richard Hughes @hughesy0707]

Delighted to be appointed as chairman of #AVCT

My core priority is to ensure the value of preCISION is exploited to its fullest, for the benefit of all shareholders.

I am more than confident we have the team and the intellectual property to enable this.

[POD65 @PaulinParis]

@coughlin582 @avacta Looking forward to May 6th. Meanwhile, here is Paul Ehrlich's plaque hiding in a quiet Frankfurt park. #AVCT is about to make his magic bullet a lot safer.

[POD65 @PaulinParis]

@ukhomeoffice What about an apology for those jailed or lives ruined.

[Christina Coughlin @coughlin582]

We are delighted to share this news. Seeing the FOCUS trial commence is a thrill for our team at #AVCT.

The work to bring this forward for patients is momentous. Everyone in the Company touched this program.

Congratulations to the team!

#FOCUSOnTheWin
#HopeWithoutCompromise

[POD65 @PaulinParis]

If / when this Gen 2 tech delivers low toxicity chemo, the TAM, total addressable market, will be boundless.

[TVR5 @TVR5AVCT]

As of 26/03/2026 @TVR5AVCT collectively represents 38,104,449 shares in @avacta (8.65% TVR).

We look forward to #AVCT dosing AVA6103 over the coming sessions, proving the Generation 2 technology which is 100% owned by Avacta until 2045.

[stonks @JStonker]

Avacta slipping in a secret third abstract. Never a dull day as an #AVCT shareholder.

https://t.co/EN6pZv7ZgZ

[RAH @RAH00084]

#AVCT

If I were in the market for AVA6000 in SGC I’d quite like:

(1) the cardiac dosing limit removed by the FDA ✅

(2) an expedited route to market ☑️

The achievement of (1) guarantees the criterion for (2) will be met.

The regulatory turnaround on (2) is 60 days.

[AM23 @AM231982]

#AVCT AVA6000 Breakthrough Therapy Designation for Salivary Gland Cancer... 60 day countdown update!

On the 3rd Feb the RNS confirmed the removal of the Dox lifetime limit for AVA6000 for SGC.

Assuming this outcome was an expected dependency before applying for Breakthrough Therapy Designation (BTD) which has a 60 calendar day review process we are now on day 43/60!!!!

This could land anytime it does not have to go to 60 days.

The facts:

1. SGC has no standard of care,
2. AVA6000 has proven zero cardio toxicity
3. Efficacy confirmed
4. The lifetime limit of AVA6000 has been removed the first time ever for a P1A trail drug.....

BTD is coming don't be surprised when it does.

(The earliest application submission date is my own assumption based on the outcome of the RNS 3rd Feb removing the lifetime limit.)

[Marty McFly @Blueberrymgmnt]

Traditional peptide drug conjugates can break down quickly because peptides tend not to be highly specific and may be cut by naturally occurring enzymes in the body. They are also cleared rapidly from the bloodstream and may release drugs too early or affect healthy tissues.

[TVR5 @TVR5AVCT]

pre|CISION’s utility is so wide as to be unquantifiable.

It is why the shape of #AVCT’s first deal is so important.

Licensing pre|CISION to someone else’s warhead was once appealing. AVA6207 renders such a route far less desirable.

Pivotal, strategic, steps have been trodden.

[Cumulus @Cumulus51896691]

I defy anyone to listen to that Cowan presentation and not conclude that Avacta are standing at the edge of something huge. #avct

[POD65 @PaulinParis]

@nw_nicholas @AmandaH53287213 You need to dig yourself out of the hole not dig in further

[nakedtrader.algo @wilko_helmut]

@SkyNews There is nothing more pioneering in the world of cancer than UK based @avacta announcing today that its had all upper dosing limits removed from its AVA6000 program.This means there is no ceiling to how long cancer treatment can go on.Thats how safe it is! Shame on you Sky! #AVCT

[RAH @RAH00084]

@PJ_Crabb If AVA6103 works as planned, #AVCT shareholders would do well to dispense with any preconceived notions around total TVR on takeover - delay that beach retirement by 12m - and focus on what it would cost to retain 100% of 6103 until P1b is complete. Potential reward is monstrous.